Skip to content
Screener

Novavax NVAX Business Segments — Other segment income (expense)

Similar metrics at other companies

New Jersey Resources logo
NJRNJNG — Other segment income (expense)
$6.8M+4.1%
New Jersey Resources logo
NJRCEV — Other segment income (expense)
$8.86M+8.0%
New Jersey Resources logo
NJRES — Other segment income (expense)
$171K-51.6%
New Jersey Resources logo
NJRS&T — Other segment income (expense)
-$139K+47.1%
Gulfport Energy logo
GPORReportable Segments — Other segment expenses
$2.3M+2,833%
California Resources logo
CRCTotal Reportable Segments — Other segment expenses
$60M-1.6%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.1%
Enterprise value$1.37B+33.0%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Novavax’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 7:33 AM EST
Fiscal year
FY2025
Accession
0001000694-26-000007
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Direct COVID-19 Vaccine(1)80,44481,736377,603
Direct CIC and influenza vaccines(1)30,01944,83138,044
Direct other vaccine development programs(1)4,6345101,042
Employee and benefit expenses145,211163,728210,589
Facility and other research and development expenses(2)82,012100,364110,224
Selling, general, and administrative expense157,479337,185468,946
Other segment income (expense)(3)(110,338)61,43221,449
Net income (loss)$440,302$(187,499)$(545,062)

Item 16. FORM 10-K SUMMARY

FAQ

What is Novavax's business segments — other segment income (expense)?
Novavax (NVAX) reported business segments — other segment income (expense) of $223.17M in Q4 2025.
How has Novavax's business segments — other segment income (expense) changed year-over-year?
Novavax's business segments — other segment income (expense) increased by 406.5% year-over-year, from -$72.81M to $223.17M.
What is the long-term trend for Novavax's business segments — other segment income (expense)?
Over 3 years (2022 to 2025), Novavax's business segments — other segment income (expense) has grown at a 102.9% compound annual growth rate (CAGR), from $13.2M to $110.34M.
What does business segments — other segment income (expense) mean?
Reflects miscellaneous income or expenses specific to the reportable segment that are not classified under core operating costs, such as non-recurring items or specific segment-level adjustments. This metric helps isolate unique financial events that impact the segment's bottom line outside of standard operations.

Ask your AI about Novavax's business segments — other segment income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude